COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS
申请人:Array BioPharma Inc.
公开号:US20200407344A1
公开(公告)日:2020-12-31
Provided herein are compounds of the Formula I:
and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X
1
, R
1
, R
2
, R
3
, R
4
, R
5
and R
6
are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
[EN] 4-OXO-3,4-DIHYDROQUINAZOLINON COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS<br/>[FR] COMPOSÉS DE 4-OXO-3,4-DIHYDROQUINAZOLINONE POUR LE TRAITEMENT DE MALADIES ET D'AFFECTIONS ASSOCIÉES À BRAF
申请人:ARRAY BIOPHARMA INC
公开号:WO2021250521A1
公开(公告)日:2021-12-16
Provided herein is a compound of the Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and L are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors.
Novel pyrimidine derivatives of formula I
to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them
将式I的新嘧啶衍生物的生产过程进行翻译,以及它们作为药物的用途,以及包含它们的药物组合物。
Pyrimidine derivatives
申请人:Novartis AG
公开号:US07910585B2
公开(公告)日:2011-03-22
Novel pyrimidine derivatives of formula I
to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.